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Background
In foamy viruses (FVs) only the integrase domain is
cleaved off from the Pol precursor protein, resulting in a
multifunctional mature reverse transcriptase (RT) har-
bouring the protease (PR) domain at its N-terminus. In
contrast to the heterodimeric RT of human immunodefi-
ciency virus type 1 (HIV-1), which consists of a 66 kDa
and a 51 kDa subunit, the PR-RT of FVs is a monomeric
protein. Thus, we wanted to analyse the inhibitory effect
of HIV-1 nonnucleoside and RNase H inhibitors on the
enzyme functions of FV PR-RT.
Results
We tested the effect of five HIV-1 RNase H inhibitors,
known to interact with different HIV-1 RT pockets [1,2],
on the PR-RT of prototype FV (PFV). All compounds
inhibited the PFV RNase H function at concentrations
comparable to the ones reported for the HIV-1 RNase H,
suggesting pocket similarity between the two proteins. In
addition, four inhibitors also inhibited the PFV associated
DNA polymerase activity. This can probably be attributed
to differences in the protein’s structure and flexibility. The
non-nucleoside RT inhibitor Efavirenz was inactive on
PFV PR-RT, implying the absence of a binding pocket
similar to the one in HIV-1 RT. NMR titration and
in silico docking experiments with the free PFV RNase H
domain and the diketo acid derivative RDS1463 identified
a putative binding site reaching into the RNase H active
site. Sequence alignments and structural overlays of HIV-1
and PFV RNase H were performed to identify the corre-
sponding binding site in HIV-1 RNase H.
Conclusions
We showed that HIV-1 RNase H inhibitors are able to
inhibit PFV PR-RT RNase H activity and in addition
polymerase functions. NMR titration and docking
experiments suggest a putative binding site for the
RNase H inhibitor RDS 1643 close to the PFV RNase H
active site.
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